Recently, the experimental armamentarium against EGFR in cancer therapy has been joined by the quinazoline OSI-774, a small-molecule EGFR-TyK inhibitor. 22, 33, 39, 41 The OSI-774 has been shown to induce cell cycle arrest and apoptosis in DiFi human tumor cells in vitro 33 and substantially to inhibit growth of HN5 human head and neck carcinoma as well as A431 human epidermoid carcinoma xenografts in nude mice. 41 A subsequent Phase I pharmacological study of OSI-774 in patients with advanced solid malignancies, including colorectal, breast, kidney, non-small cell lung, ovarian, gastric, head and neck, prostate, anal, cervical, pancreatic, and hepatocellular carcinoma, has demonstrated good tolerability when administered in a daily oral dose of 150 mg as well as antitumor activity or relatively long periods of stable disease. 22 Despite primary GBM being one of the most illustrative biological examples for quantitative and qualitative EGFR alterations, 23, 46, 51, 57, 61, 62 however, neither in vitro nor in vivo data are currently available on the effects of OSI-774 on GBM.
Even with advances in neurosurgery, radiation oncology, and chemotherapy, GBM remains among the most devastating of malignant tumors occurring in humans. 47, 48 Amplification of the EGFR gene is frequently present in GBM, 5, 46, 50 occurs almost exclusively in this type of brain tumor, and thus appears to be a late event in glial tumor progression. 46 Although the amplification of up to 12 additional genes including cyclin-dependent kinase 4, murine double minute 2, and sarcoma-associated sequence has been demonstrated in GBM, 8 the EGFR gene remains by far the most common amplification target in this tumor type.
In a previous study, 33 the TyK domains of the human insulin receptor and insulin-like growth factor-I receptor were shown to remain essentially unaffected even by high concentrations of OSI-774. Moreover, contact-inhibited Fischer rat embryo cells retained a continued capacity for cell proliferation in response to PDGF in the presence of OSI-774, altogether suggesting that other receptors and ligands involved in the oncogenic process (for example, PDGFR, 37, 38 PDGF, 19, 38 TGF␤, 3, 20, 24, 25, 60 and TNF␣ 40 ) may modulate the response of cancerous cells to EGFR inhibition. Besides these exemplary cytokines and receptors, the status of the tumor suppressor gene p53 may be of critical importance to the antiproliferative or apoptotic response of a GBM cell to EGFR pathway inhibition, 10, 63 especially given that EGFR gene amplification and p53 gene mutation are considered to be mutually exclusive in GBM 59 and apparently represent different molecular pathways of pathogenesis. 15, 29, 43, 46, 58 Platelet-derived growth factor is a well-characterized mitogen that occurs as five isoforms of disulfide-linked A, B, C, and D chains (that is, PDGF-AA, -BB, -CC, -DD, and -AB), 17, 31 which bind with different affinities to two types of cell surface receptors (PDGFR␣ and ␤). The PDGFR␣ binds PDGF-AA, -BB, -CC, and -AB with high affinity, whereas the PDGFR␤ binds PDGF-BB and -DD with high affinity and PDGF-AB with lower affinity. The two receptors are structurally and functionally related and belong, as does the EGFR, to the protein TK superfamily of growth factor receptors. Glioblastoma cells frequently express the PDGFRs (predominantly PDGFR␤) and their ligands, indicating the presence of autocrine/paracrine growth factor stimulation related to tumor progression. 21, 37 The oncogenic potential of PDGF-BB is further underscored by the observation that astrocytes infected with retroviruses carrying the PDGF-B gene form brain tumors in vivo. 54 Transforming growth factor-␤ is a cytokine that is released by glioma cells in large quantities in vitro and in vivo and has been considered to be related to the malignant progression of glial tumors and the immune dysfunction in patients with GBM by promoting tumor angiogenesis, enhancing migration and invasion, and inhibiting T cell-mediated immune responses. 60 Interestingly, TGF␤ may exert its mitogenic effect on GBM cells in vitro through the induction of the EGFR. 20 Tumor necrosis factor-␣ is produced predominantly by monocytes and/or macrophages, but also by transformed astrocytes and miscellaneous nonhematopoietic tumor cell lines. 30 Tumor necrosis factor-producing cells are commonly resistant to TNF, 45 indicating that the local and systemic effects of this cytokine, that is, killing of primary oligodendrocytes 44 and induction of cachexia, 9 may alter tumor-host interactions in favor of the expanding brain tumor.
A major cellular function of the p53 tumor suppressor protein is to suspend progression through the cell cycle (that is, from the G1 to the S phase) subsequent to genomic damage so that DNA repair can take place before replication. 28 If the DNA is irreparably damaged, p53 may trigger cell death by apoptosis, thus maintaining genomic stability and mediating the responsiveness of certain malignancies to ionizing radiation and chemotherapeutic agents. 26 These tumor suppressor activities of wild-type p53 are abrogated by mutations within the p53 gene. 7 The aim of the current study was to evaluate molecular and cellular effects of OSI-774 on nine GBM cell lines established from histopathologically confirmed neurosurgical specimens obtained in our department. To begin, we examined the effect of OSI-774 on the expression of EGFR itself as well as on cellular proliferation, anchorage-independent growth, and apoptosis in vitro. In addition, baseline expression levels (in standard cell culture conditions) of EGFR (and its ligand TGF␣), PDGF-AA, PDGFR␤ (and its ligand PDGF-BB), TGF␤, and TNF␣ were established. Last, we determined the mutational status of the p53 gene by performing bidirectional DNA sequencing. The effects of OSI-774 on established tumors derived from two exemplary cell lines were confirmed in a heterotopic nude mice model. Statistical analysis included clinical parameters of corresponding patients.
Materials and Methods

The EGFR Tyrosine Kinase Inhibitor OSI-774
The OSI-774 ([6,7-bis(2-methoxy-ethoxy)-quinazoline-4-yl]- [3-ethylphenyl] amine, C 22 H 23 N 3 O 4 , formerly known as CP-358,774 and also known as erlotinib and Tarceva), 33 a colorless, crystalline, anhydrous compound, is an orally active reversible EGFR-TyK inhibitor kindly provided by OSI Pharmaceuticals (Uniondale, NY). For the in vitro studies described here, a 1-mmol/L stock solution of OSI-774 in its hydrochloride salt form (molecular weight 429.9 g compared with 393.4 g in the free base form) was prepared by dissolution of the dry powder in DMSO by vortexing. Unless otherwise stated, concentrations given refer to the salt form.
For murine intraperitoneal administration, OSI-774 was formulated by suspending the powder in 0.5% methylcellulose solution and stirring for 1 hour.
Glioblastoma Cell Lines
Nine established GBM cell lines 12, 13 derived from histopathologically rereviewed (according to the 2000 World Health Organization classification of nervous system tumors) and confirmed neurosurgical specimens obtained in our department were maintained in RPMI-1640 cell culture medium (BioWhittaker, Walkersville, MD) supplemented with 10% heat-inactivated FCS and incubated in a humidified 5% CO 2 atmosphere at 37˚C. The medium was exchanged twice weekly, and cells were passaged on reaching subconfluence. At the beginning of the study, all cell lines were beyond their 20th passage. The neuropathological diagnoses of GBM were supported by immunocytochemical staining for glial fibrillary acidic protein and vimentin.
In methodological continuation of proliferation studies previously conducted on DiFi human colorectal carcinoma cells, 33 experiments involving OSI-774 were performed in 0.5% FCS. Appropriate amounts of OSI-774 stock solution were added to the cell culture medium at the beginning of each experiment to obtain various final concentrations, and controls were set up with and without the addition of equivalent amounts of DMSO (maximum of 3‰ [vol/vol] corresponding to 3 mol/L OSI-774) to the culture medium (0.5% FCS). In selected experiments, additional characterizations were performed in standard cell culture conditions (that is, 10% FCS without both OSI-774 and DMSO).
Clinical parameters in corresponding patients were obtained by standardized chart review.
Extraction of RNA and Synthesis of cDNA
In a variety of controlled experimental conditions (that is, 10% FCS, 0.5% FCS with 3 mol/L OSI-774, and 0.5% FCS with and without the equivalent amount of DMSO [examined in all but the first condition on Days 3 and 7 of exposure]), total cellular RNAs were isolated from the aforementioned cell lines by using a monophasic solution of phenol and guanidine isothiocyanate (TRIZOL reagent; Life Technologies, Grand Island, NY), quantified using spectrophotometry, adjusted to equal concentrations, treated with RNAse-free DNAse I (Promega, Madison, WI), and subjected to RT by using oligo(deoxythymidine) primers (Superscript Preamplification System; Life Technologies), according to the manufacturer's recommendations. Ribonucleic acids were isolated on Days 3 and 7 of exposure to the respective experimental condition because at 10% FCS the cell lines were essentially growing in an exponential fashion in between these time points. The absence of residual genomic DNA contamination was monitored using "no RT controls" in which reverse transcriptase had been omitted.
Semiquantitative PCR
The resulting cDNAs were amplified with the aid of PCR by using GeneAmp core reagents (Perkin-Elmer Cetus, Norwalk, CT) with 2 U of Taq DNA polymerase and two sets of primers (final concentration of 0.5 mol/L per primer) for the EGFR target (20-mers; sense 5Ј-TGCAACCTTCTGGAGGGTGA-3Ј; antisense 5Ј-GTGTTG-TTTTCTCCCATGAC-3Ј; corresponding to nucleotides 1801-1820 and 1981-2000 of EGFR cDNA, 55 respectively; custom-synthesized by MWG Biotech [Göttingen, Germany]) and the ␤-actin reference genes (32-mers; sense 5Ј-ATCTGGCACCACACCTTCTACAAT-GAGCTGCG-3Ј; antisense 5Ј-CGTCATACTCCTGCTTGCTGA-TCCACATCTGC-3Ј; corresponding to nucleotides 294-325 and 1100-1131 of ␤-actin cDNA, 35 respectively; Clontech [Palo Alto, CA]), respectively, in a 50-l reaction volume. The sizes of the PCR products were 200 bp and 838 bp for EGFR and ␤-actin, respectively. Optimized PCR conditions involved denaturation at 95˚C for 1.3 minutes, annealing at 56˚C for 1 minute, and extension at 72˚C for 2 minutes; amplification was performed for 35 cycles, followed by a final extension step at 72˚C for 10 minutes. When subjected to ethidium bromide-stained 1.8% gel electrophoresis in 1 ϫ Tris-borate ethylenediaminetetraacetic acid buffer and ensuing ultraviolet transillumination, the PCR products yielded sharp and distinct bands of the expected molecular weights, which were densitometrically assessed for differences in band intensities. To determine relative target (that is, EGFR) mRNA expressions, densitometric target/reference RT-PCR product ratios were normalized by adjusting for divergent fragment sizes. Band identities were confirmed by DNA sequencing. Experiments were performed in duplicates.
Sequencing of the p53 Genes
Sequence analysis of the entire p53 gene was performed as PCRdirected sequencing of genomic DNAs of the cell lines (SEQLAB, Göttingen, Germany). The first round of PCR generated exon 1 as a separate amplicon, whereas exons 2 through 4, 5 and 6, 7 through 9, and exons 10 and 11, respectively, were amplified together in larger portions. These amplicons served as templates for a second round of PCR with fully nested and M13-sequence 5Ј-tailed primers. The second-round PCR products were shorter than the first-round products to facilitate complete double-stranded sequencing. After standard purification of the PCR products (Qiagen, Valencia, CA), the sequencing reactions were performed with the 21M13 for and the M13 rev sequences as primers and 20 ng of PCR product per 100 bases of length (BIG DYE; Applied Biosystems, Weiterstadt, Germany). The sequencing products were precipitated with alcohol, redissolved in standard formamide/Tris-Cl sample buffer, and loaded onto 48-cm 4% polyacrylamide gels for the 377 automatic sequencer (Applied Biosystems). Gels were run for 4 to 6 hours at 3000 V. Sequencing results were analyzed using sequence analysis software; alignment with, and comparison to, the reported wild type p53 sequence 64 was performed using the AutoAssembler (both from Applied Biosystems).
Immunocytochemical Analysis
To establish baseline expressions of EGFR, PDGFR␤, PDGF-AA, PDGF-BB, TGF␣, TGF␤, and TNF␣, respectively, 5 ϫ 10 4 cells were seeded in duplicates on glass slides within glass-adherent silicon rings (0.77-cm 2 growth area, flexiPERM con A; Hereaus Instruments, Osterode, Germany) and incubated in RPMI-1640 with 10% FCS. On reaching subconfluence, cells were rinsed with HBSS, fixated in acetone (Ϫ20˚C) for 3 minutes, and air-dried overnight. Endogenous peroxidase activity was blocked by incubation in PBS with 0.3% hydrogen peroxide for 10 minutes, ethanol with 0.3% hydrogen peroxide for 10 minutes, or ethanol with 0.3% hydrogen peroxide for 20 minutes followed by 0.05% saponin solution for 30 minutes, respectively, depending on the primary antibody used. The primary antibody was applied to the cells in a humidified chamber for 1 hour. After three rinsing steps in PBS, cells were incubated with the appropriate (that is, species-specific with respect to the primary antibody) secondary biotinylated antibody for 30 minutes, followed by another three rinsing steps in PBS. Next, cells were incubated with avidin and biotinylated horseradish peroxidase macromolecular complex (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) for 40 minutes, repeatedly rinsed with PBS, and exposed to chromogenic peroxidase substrate (3-amino-9-ethyl-carbazole with 0.015% hydrogen peroxide). After rinsing in sodium acetate buffer for two periods of 5 minutes each and light counterstaining of cells with the Gill hematoxylin, slides were mounted. Antibodies were diluted 1:20, 1:50, or 1:100 in 0.5% albumin in PBS. For negative controls, the primary antibody was replaced with polyclonal immunoglobulin G of the corresponding species. Unless otherwise noted, incubations were performed at room temperature. To assess the influence of OSI-774 on EGFR expression levels, cells were seeded as described earlier, and the medium was ex-changed after 24 hours so that it contained 0.5% FCS with 3 mol of OSI-774 or 0.5% FCS with and without the equivalent amount of DMSO, respectively. Cells were fixed on Days 3 and 7 of exposure to the respective condition and were subsequently treated as described earlier, with a blockade of endogenous peroxidase activity by incubation in PBS with 0.3% hydrogen peroxide for 10 minutes. The medium was exchanged every 2 days.
Immunocytochemical results were assessed independently by two observers using up to 400ϫ magnification on a semiquantitative 13-score scale, which accounted for both staining intensity (0, no staining; 1, light staining; 2, moderate staining; and 3, strong staining) and quarters of total cells stained (0-4). For standardization purposes, these scores were condensed as follows: 0, л; 1-4, ϩ; 5-8, ϩϩ; and 9-12, ϩϩϩ. Interobserver disagreements on scoring (Ͻ 10% of cases) were resolved by microscopic review and discussion.
Cell Proliferation
To obtain growth curves from standard cell culture conditions, 1.5 ϫ 10 5 viable GBM cells were seeded in 6-well flat-bottomed culture plates (Becton Dickinson, Lincoln Park, NJ) in RPMI-1640 with 10% FCS.
For OSI-774 proliferation/inhibition studies, cell lines were seeded as described earlier. After 24 hours, the cell culture medium was exchanged so that it contained 0.5% FCS plus various concentrations of OSI-774 (0.5, 1, 2, and 3 mol/L), or 0.5% FCS with and without the equivalent amounts of DMSO, respectively. Cell numbers were determined at least every 2 to 3 days during a 10-day period using a Z1 Coulter Counter (Coulter, Krefeld, Germany).
During proliferation experiments, cell culture media were exchanged daily. Experiments were performed in duplicate.
Anchorage-Independent Growth
To determine the anchorage-independent growth of GBM cells in soft agar, 10 4 viable cells were suspended in RPMI-1640 containing 10% FCS and 0.35% agarose (SeaPlaque GTG agarose; FMC BioProducts, Rockland, ME) and were pipetted onto the top of a prepared RPMI-1640/0.5% FCS/0.9% agarose base in 60-mm cell culture dishes. 49 After microscopic confirmation of single-cell dispersion, the culture dishes were incubated for 14 days. The number of colonies (defined as aggregates containing Ն 40 cells) were then counted and extrapolated from 10 predefined visual fields by using an inverted microscope and a custom-made opaque cover with 10 representatively distributed 0.5-mm holes. Anchorage-independent growth was quantitatively assessed by determining the fraction of seeded cells that yielded colonies (cloning efficiency). The effect of OSI-774 on the anchorage-independent growth of GBM cells was assessed by proceeding as described, except that the soft agar was prepared so that it contained 0.5% FCS and 0.5, 1, 2, and 3 mol/L OSI-774, respectively. Control cells were seeded with and without the addition of equivalent amounts of DMSO and were otherwise treated identically.
Apoptosis in GBM Cells
Following exposure of semiconfluent GBM cells to 3 mol/L of OSI-774 for 48 hours or 0.5% FCS with control DMSO, DNA fragmentation was directly detected using TUNEL 18 with the aid of a fluorescein in situ cell death detection kit (Roche, Mannheim, Germany), based on optimization of the manufacturer's recommendations. In brief, cells were detached, adjusted to 10 7 cells/ml, and transferred to V-bottomed 96-well microtiter plates (100 l/well). After adding 100 l/well of freshly prepared paraformaldehyde solu- 
Tumor Growth In Vivo
The tumor growth inhibitory effect of OSI-774 was evaluated in 6-week-old female athymic mice (Charles River Wiga GmbH, Sulzfeld, Germany) bearing established, palpable human G-599GM or G-750GM tumors. Mice were allowed to acclimate for at least 3 days after their arrival and were treated between 7:00 and 9:00 a.m. immediately after a 12-hour dark photoperiod (active phase) to control for any variability introduced by circadian physiological cycles. 16 Mice were housed in specific pathogen-free conditions and were treated according to approved institutional experimental animal care and use protocols. During these studies, animals were provided pelleted food and water ad libitum.
To induce tumors, cells were harvested from exponentially growing subconfluent cultures by performing light trypsinization (0.25% trypsin and 0.02% ethylenediaminetetraacetic acid for 1 minute), washed with and resuspended in ice-cold HBSS, examined for viability, counted, adjusted to the final concentration, kept on ice for less than 30 minutes, and subcutaneously injected into the left flank of each mouse (7.5 ϫ 10 6 G-599GM or 2.5 ϫ 10 6 G-750GM cells in 250 l HBSS). Treatment was initiated after the tumors had reached diameters of 3 to 4 mm (Day 9 [G-599GM] or Day 5 [G-750GM] after implantation). Tumor sizes were measured in millimeters by using Vernier calipers across three diameters every 6 days, and the tumor volume (mm 3 ) was calculated using the following formula: 1/2 (length ϫ width ϫ depth). 53 The OSI-774 was intraperitoneally administered once daily (50 mg/kg body weight in 200 l 0.5% methylcellulose) for 18 consecutive days. Correspondingly, control animals received mock intraperitoneal injections of 200 l 0.5% methylcellulose only.
Statistical Analysis
Appropriate pairs of variables with biologically founded putative relationships were analyzed by calculating estimators for Pearson correlation (r) and Spearman rank correlation (R) coefficients. Independence of paired variables was evaluated using permutation tests (SAS, version 8.01; SAS Institute, Inc., Cary, NC). Scatter plots were generated with the aid of commercially available software (Statistica, version 6.0; StatSoft, Inc., Tulsa, OK).
Results
Expression of EGFR mRNA
Analysis of EGFR mRNA expression by GBM cell lines in long-term culture (10% FCS) by performing densitometry of electrophoretically separated semiquantitative RT-PCR products revealed a median expression level of 1.3 (range 0.63-1.63) relative to ␤-actin mRNA, with a convincing correlation with immunocytochemical scoring (Table 1) . Although densitometric values for the ␤-actin reference bands remained constant in the four different experimental conditions used in this study (data not shown), relative serum starvation (0.5% FCS) markedly changed EGFR mRNA expressions as determined on Days 3 and 7 of exposure to this condition; the addition of control amounts of DMSO did not yield significant effects (data not shown). The difference between densitometric EGFR/ ␤-actin RT-PCR signal ratios obtained from cells exposed to relative serum starvation (0.5% FCS) for 3 days and those maintained at standard conditions (10% FCS) defined EGFR mRNA induction (six cell lines) or downregulation (three cell lines; median 0.51, range 0.76-1.34). Relatively, changes in EGFR mRNA expression had a median of 31% (G-1408GM) and ranged from Ϫ72% (G-1301GM) to 146% (G-599GM). There were positive correlations between normalized densitometric EGFR/␤-actin RT-PCR signal ratios obtained from cells exposed to 3 mol/L OSI-774 for 3 or 7 days, and the corresponding control conditions (Tables 1 and 2 ; r = 0.88 and 0.98, respectively). Importantly, EGFR mRNA induction as defined earlier was inversely correlated in GBM cell lines to the inhibition of anchorage-independent growth by OSI-774 (r = Ϫ0.74).
Sequencing of the p53 Genes
In addition to a number of sequence polymorphisms (data not shown), bidirectional sequencing of the 11 exons of the p53 tumor suppressor genes revealed coding homozygous missense mutations in seven of the nine GBM cell lines (Table 3) . Presumably, the allelic status of these mutations was a result of the loss of heterozygosity. Although a heterozygous Gly➝Ser amino acid substitution with uncertain physiological relevance was found in G-1265GM, the p53 gene of G-1408GM contained only polymorphisms and was judged to be wild type.
Immunocytochemical Analysis
Immunocytochemical studies at standard cell culture conditions (10% FCS) revealed target protein expressions ranging from л to ϩϩϩ (PDGF-AA and PDGF-BB), from ϩ to ϩϩϩ (PDGFR␤ and TGF␤), and from ϩ to ϩϩ (TGF␣ and TNF␣) (data not shown). As determined on statistical analysis, there was no considerable correlation between baseline expression of any of these proteins and responses of GBM cell lines to OSI-774. Specifically, correlations with | R| Ͻ 0.1 are shown in Table 4 data not shown). Likewise, concordance was observed between EGFR mRNA and protein expressions as determined on RT-PCR densitometry and immunocytochemical analysis, respectively (Table 1) . Regardless, the sensitivity of the latter method is clearly inferior to that of the former, with a cutoff sensitivity threshold of 0.67 EGFR mRNA copies relative to ␤-actin mRNA (Table 1) .
Cell Proliferation
Growth curves reflecting standard (10% FCS) and control (0.5% FCS with DMSO equivalent) conditions are featured in Figs. 1 and 2 , respectively. Control conditions led to a marked disparity in growth curves, indicating different degrees of relative growth factor independence among the cell lines. The addition of control amounts of DMSO had no significant effect on proliferation compared with naive controls (0.5% FCS; data not shown). Tumor cell line G-750GM was the fastest growing one in both conditions, with doubling times of 1.2 and 1.71 days, respectively, during the exponential growth phase. In contrast, cell line G-599GM grew the slowest in standard conditions and the second fastest in control conditions (doubling time 2.04 and 2.19 days, respectively), thus exhibiting widely growth factor-independent proliferation. Cellular proliferation at 3 mol/L OSI-774 is represented in Fig. 3 . According to their cell numbers compared with DMSO controls on Day 10 (antiproliferative response to OSI-774), the GBM cell lines may be categorized as follows: Group I (growth inhibition Յ 33.3%): G-211GM, G-1163GM, G-1187GM, G-1265GM, and G-1301GM; Group II (growth inhibition Ͻ 33.3% and Ͼ 66.7%): G-210GM, G-750GM, and G-1408GM; Group III (growth inhibition Ͼ 66.7%): G-599GM. As evident from Fig. 3 , substantial G-599GM cell death occurred by Day 4 at 3 mol/L OSI-774, resulting in cell numbers below the quantity seeded. At 0.5 mol/L, growth inhibition was 36% with preserved net cell growth; at greater than or equal to 1 mol/L, cell death resulted in a net cell loss (data not shown). Overall, cell numbers obtained after 10 days of exposure to OSI-774 (3 mol/L) were strongly correlated to those of the corresponding DMSO controls (r = 0.84).
Anchorage-Independent Growth
Anchorage-independent growth as determined using the soft agar colony formation assay in vitro in standard conditions (10% FCS) ranged from 0 to 35% (G-1265GM and G-750GM, respectively), with a median of 14% (G-1163GM; Table 1 ). Repeated experiments showed identical results for G-1265GM (unpublished observation).
In control conditions (0.5% FCS with equivalent amounts of DMSO), anchorage-independent growth decreased between 17 and 50% (G-750GM and G-1301GM, respectively) relative to the values obtained in standard conditions. The relative decrease in anchorage-independent growth for G-599GM was 40% (data not shown), indicating that growth factor-independent proliferation does not * Variables shown were determined using immunocytochemical analysis at 10% FCS.
† Parameters listed were analyzed at 3 mol/L OSI-774, except for inhibition of clonogenicity, which was determined at 1 mol/L. Cell multiplication was based on cell numbers by Day 10. Doubling times were calculated from cell numbers on Days 3 and 7 (exponential growth phase at standard cell culture conditions). Inhibition of clonogenicity was determined by comparison with DMSO controls on Day 14; apoptosis was analyzed after 48 hours of exposure. imply growth factor-independent in vitro tumorigenicity of this cell line. The addition of control amounts of DMSO had no significant effect on anchorage-independent growth compared with naive controls (0.5% FCS; data not shown).
At 2 and 3 mol/L of OSI-774, anchorage-independent growth was completely abolished in all of the cell lines. The inhibition of anchorage-independent growth by 1 mol/L of OSI-774 was inversely correlated to EGFR mRNA induction (r = Ϫ0.74). In contrast, the estimators for Spearman rank correlation coefficients were close to 0 for the inhibition of anchorage-independent growth at 1 mol/L OSI-774 and baseline expressions of PDGFR␤ or TGF␣ as determined on immunocytochemical studies (R = 0.08 and 0.03, respectively; Table 4 ).
Apoptosis in GBM Cells
As determined using the TUNEL method, OSI-774-induced programmed cell death after 48 hours of exposure to 3 mol/L ranged from 34.83 to 48.92% (G-1408GM and G-599GM, respectively), with a median of 37.72% (G-1265GM; Table 2 ). Statistical analysis revealed positive correlations for the extent of OSI-774-induced apoptosis and cell numbers of DMSO controls on Day 10 or anchorage-independent growth of GBM cell lines at 10% FCS (r = 0.75 and 0.79, respectively), indicating preferable causation of apoptosis in more malignant cellular phenotypes. Based on bidirectional sequencing of the entire p53 gene as described earlier, the apoptotic process described here must be viewed as p53-independent.
Tumor Growth In Vivo
In an athymic mouse heterotopic tumor model, the intraperitoneal administration of OSI-774 yielded differential antitumor effects against established, subcutaneously palpable human GBM derived from two exemplary cell lines (G-599GM and G-750GM; Fig. 4 ). Both control tumor growth and tumor response to treatment corresponded well with the proliferative behavior in vitro (Figs. 2 and 3 ) in that G-750GM tumors grew faster and exhibited relative resistance against OSI-774-mediated growth inhibition, whereas G-599GM tumors were characterized by delayed development and progression in control conditions as well as discernible regression in response to treatment. There was no compound-related death during the treatment period. Subsequent to proof-of-principle in vivo, animals were killed after 18 days of treatment to reduce their suffering.
Clinical Characteristics
No considerable correlation was present between experimental parameters and clinical characteristics of corresponding patients (that is, age, sex, duration between onset of symptoms and tumor-related death, tumor localization and size, extent and timing of resection(s) as well as type(s) and timing of adjuvant therapy). Among the panel of GBM cell lines included in this study, G-599GM was the only one derived from a tumor of probable oligodendrocytic origin, as indicated on histopathological analysis.
Discussion
In this study, by examining molecular and cellular effects of a novel small molecule EGFR-TyK inhibitor on nine GBM cell lines, we highlighted the complex biology and heterogeneity of GBM. The majority of GBM cell lines required higher concentrations of OSI-774 than the human DiFi colorectal carcinoma and the HN5 head and neck cancer cell lines 33 to show a significant antiproliferative response in vitro. Consequently, the experiments described here were conducted with 3 mol/L OSI-774 and complemented by gradual decreases in concentration when examining more concentration-sensitive cellular properties (that is, proliferation of G-599GM and anchorage-independent growth in general). Using different primary antibodies with correlating results validated immunocytochemical studies for EGFR; likewise, concordance was present between EGFR mRNA and protein expressions, as determined on RT-PCR and immunocytochemical analysis, respectively. This latter result was in accordance with data from a previous study demonstrating a close correlation between the degree of EGFR expression and gene amplification. 46 Note that no substantial correlation was observed between baseline expressions of EGFR (that is, in standard cell culture conditions) on either RT-PCR or immunocytochemical analysis and cellular responses to OSI-774 in vitro (that is, inhibition of proliferation, apoptosis, and suppression of anchorage-independent growth). In contrast, the ability of GBM cells to induce EGFR mRNA by Day 3 of relative serum starvation (0.5% FCS) was associated with decreased susceptibility to the anticlonogenic effect of OSI-774. The induction of EGFR mRNA (and, ultimately, EGFR) may be regarded as a cellular effort to counteract functional EGFR inhibition by OSI-774. Taken together, our study data demonstrate EGFR induction during relative ligand starvation rather than low EGFR baseline expression as a possible determinant of relative cellular resistance to this compound.
Based on results of previous studies, 14, 36 quantitative and qualitative alterations of EGFR in GBM are much less likely to modulate proliferation in vitro than to affect anchorage-independent growth. This notion is supported by the observation that anchorage-independent growth was completely suppressed by concentrations of OSI-774 that led to no or only mild inhibition of proliferation in eight of nine GBM cell lines. Against this background, however, the biological basis for downregulation of EGFR mRNA by three GBM cell lines on exposure to OSI-774 requires further clarification.
The strong positive correlations of normalized densitometric EGFR/␤-actin RT-PCR signal ratios obtained from cells exposed to 3 mol/L of OSI-774 for 3 or 7 days and the corresponding control conditions support the assumption that EGFR-TyK inhibition (by OSI-774) and EGFR ligand withdrawal (by relative serum starvation) yield similar cellular effects, notwithstanding the fact that serum starvation affects a multitude of signaling pathways besides those addressed by EGFR. Corroborating evidence is provided by the correlation between cell numbers after 10 days of exposure to OSI-774 and those of the corresponding DMSO controls.
Bidirectional sequencing of the entire p53 tumor suppressor gene revealed coding homozygous missense mutations in seven of nine GBM cell lines, indicating that apoptosis induced by OSI-774 may be executed p53-independently. Mutations of p53 usually occur in secondary GBM, which evolve through progression from lower-grade astrocytomas in younger patients, 4, 27, 59 and thus at least some of the mutations we detected were likely to have been acquired during cell culture. On the contrary, EGFR gene aberrations, representing typical features of primary or de novo GBM, which arise rapidly in older patients, are commonly lost during cultivation of GBM cells. 6 Cell line G-599GM displayed characteristic features of a secondary GBM, that is, histopathological indications of oligodendrocytic origin, mutation of p53, the lowest level of EGFR mRNA in the panel of cell lines being examined, and a young patient age. 4, 27, 59 Importantly, G-599GM showed the strongest antiproliferative and apoptotic response to OSI-774 among the GBM cell lines used in this study. Despite achieving the greatest relative EGFR mRNA induction during serum starvation, G-599GM sustained substantial cell death on exposure to OSI-774 long before reaching the absolute EGFR mRNA levels generated by G-211GM (a cell line showing virtually no antiproliferative response to 3 mol/L of OSI-774), demonstrating that the ability of G-599GM to induce EGFR mRNA may have been overtaxed by the combination of at least 1 mol/L OSI-774 and cellular requirements for EGFR signaling.
The opposite side of the spectrum, both pathogenetically and in terms of biological phenotype, is probably best represented by cell line G-750GM, which exhibits distinctive properties of a primary GBM, that is, a relatively high level of EGFR mRNA, markers of rapid tumor progression (highest values for in vitro proliferation and anchorageindependent growth), and an older patient age. 4, 27, 59 This cell line did not markedly induce EGFR mRNA on exposure to OSI-774, showed significant therapeutic responses, and retained the highest proliferative activity.
In a confirmatory in vivo experiment, the biological behavior of established tumors derived from these two exemplary cell lines corresponded well with the proliferative characteristics in vitro, both in terms of control tumor growth and response to treatment.
In between these paradigms remains a set of cell lines with quantitatively and qualitatively heterogeneous profiles of sensitivities and resistances to OSI-774, and further dissection of the genetic basis of cellular response is strongly warranted in larger sample collectives.
Recently, genetic attributes such as alteration of the tumor suppressor gene PTEN/MMAC1/TEP1 (that is, phosphatase and tensin homolog deleted on chromosome 10/ mutated in multiple advanced cancers/TGF␤-regulated and epithelial cell-enriched phosphatase) have been linked to resistance of EGFR-overexpressing tumor cells to small molecule EGFR-TyK inhibitors. 2 Although DNA copy number alterations for the 10q23.3 gene locus at which PTEN resides are present in six of our cell lines, as determined by comparative genomic hybridization, 42 no considerable correlations could be established between the presence of 10q23.3 copy number alterations or baseline expressions of EGFR, PDGFR␤, PDGF-AA, PDGF-BB, TGF␣, TGF␤, or TNF␣ and cellular responses to OSI-774. Longitudinal studies on the expression of these proteins during cellular exposure to this compound are required to elucidate their potential contribution to cellular resistance.
The positive correlations for the extent of OSI-774-induced apoptosis and control cell numbers on Day 10 or baseline anchorage-independent growth indicate preferable causation of apoptosis in more malignant cellular phenotypes. Although OSI-774 is unlikely to discriminate molecularly between wild type EGFR on normal and malignant cells, this inferred phenotypical selectivity-the molecular basis of which is as yet undefined-may prove therapeutically advantageous. We are currently examining potential differences between effects exerted by OSI-774 on GBM cells expressing wild type or constitutively active deletion-mutant EGFR (variously termed "⌬EGFR," "de2-7 EGFR," or "EGFRvIII"). 34, 36, 50, 61, 62 Five of the nine GBM cell lines examined in this study showed no or only light antiproliferative responses to 3 mol/L OSI-774. Nonetheless, anchorage-independent growth of three cell lines was completely suppressed at 1 mol/L. At 2 mol/L, none of the cell lines retained clonogenic capacity. These results indicate that OSI-774 may prevent or delay recurrences following gross-total resection of GBM even more than having cytostatic effects on established tumors. In a Phase I and pharmacological study of OSI-774 in patients with advanced solid malignancies, 22 average minimal steady-state plasma concentration of OSI-774 (free base) was 1.2 g/ml (3 mol/L) and thus identical to the concentration that we used in vitro. Although no published data are available on the penetration of the intact blood-brain barrier by OSI-774, this barrier is frequently impaired in patients with GBM because of perifocal edema, which may have a potentially favorable impact on local pharmacokinetics.
Conclusions
The OSI-774, a novel EGFR-TyK inhibitor, possesses therapeutic potential against GBM cell lines in vitro at or below the average minimal steady-state plasma concentration of OSI-774 achievable in humans. The antiproliferative and p53-independent apoptotic effects of this compound may be enhanced against secondary GBM. Overall, the suppression of anchorage-independent growth was a stronger effect than the inhibition of proliferation, indicating that OSI-774 may have a potential therapeutic role in preventing or delaying a recurrence following gross-total resection of GBM rather than having cytostatic effects on established tumors. The extent of OSI-774-induced apoptosis was positively correlated to cellular malignancy. Induction of EGFR mRNA may constitute an effective cellular mechanism to counteract the inhibitory effect of OSI-774 on anchorage-independent growth of GBM cells. In contrast, no substantial correlation could be established between baseline expressions of EGFR (both mRNA and protein) in GBM cell lines and their biological responses to OSI-774.
